image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 6 days, don't miss out!

Plus500

September 2025

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • PLUS
  • Price:
  • 3424p
The shares powered towards £35 after Plus500’s Q2 update showed strong operational delivery and geographic expansion with new and active customers up 18% and 7%, respectively, versus Q2 24 while client deposits doubled to US$3.1bn.  Aided by April’s roiled markets when Trump tariffs threatened a crash, Plus grew EBITDA 12% year-on-year in Q2 to US$91.3m while net cash increased by US$35m between FY24 and H1 25 despite US$200m of share buy backs / dividends announced in the first half.  Plus has also acquired a new OTC regulatory licence in Canada at the end of June strengthening its US presence and which means it now has 15 licenses up from just two at IPO. Further services are expected to be launched in future.  Alt ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author

LIMTED TIME OFFER

SUBSCRIBE TODAY AND SAVE £30 USING OFFER CODE 30OFFTMI

To access our archive of articles and receive current issues you need to subscribe